Leukemia
The Food and Drug Administration (FDA) has expanded the use of the anticancer drug Imbruvica (ibrutinib) to be used in combination with rituximab for the treatment of the most common type of leukemia in adults, chronic lymphocytic leukemia (CLL), or its variant called small lymphocytic lymphoma (SLL). Read More ›
Targeted therapies continue to change the treatment landscape, improving outcomes beyond traditional chemoimmunotherapy. Read More ›
Although most employers are not passing costs to employees, the COVID-19 pandemic has raised uncertainty throughout the entire healthcare system. Read More ›
An analysis of 4 studies finds that acalabrutinib does not increase the risk of developing heart problems for patients with CLL. Read More ›
A 5-year analysis of the MURANO study shows patients completing venetoclax treatment have long-term, durable responses. Read More ›
A systematic review of publications finds that patients with hematologic cancers who contract COVID-19 have an increased risk of death. Read More ›
Over the past 20 years, advances in the treatment of chronic myeloid leukemia (CML) have made this type of cancer highly treatable, such that most patients can live long and productive lives. Today, people diagnosed with CML who are treated with targeted medications have similar life expectancies as people without CML. Read More ›
By Chase Doyle
Just because a cancer drug is approved by the FDA does not mean its therapeutic benefit is completely understood. Improving outcomes and minimizing side effects of a drug often requires using the drug in different doses or in combination with other drugs. Read More ›
By Chase Doyle
The targeted therapy Calquence (acalabrutinib), a Bruton tyrosine kinase (or BTK) inhibitor, which is approved by the FDA for the treatment of patients with non-Hodgkin lymphoma has now demonstrated long-term remissions as first-line treatment of patients with chronic lymphocytic leukemia (CLL), according to data presented at the 2020 ASCO annual meeting. Read More ›
By Dana Taylor
Results of a recent study show that the use of Imbruvica plus Venclexta in patients with CLL who had not received any previous therapy for CLL had long-term remissions of the disease.
Read More ›